Pioglitazone Hydrochloride is a thiazolidinedione (PPAR-gamma agonist) indicated for type 2 diabetes mellitus. We supply it to US manufacturers of tablets and fixed-dose combinations.
Data from PubChem (CID 60560) and FDA’s substance registry
CAS number
112529-15-4
Molecular formula
C19H21ClN2O3S
Molecular weight
392.9g/mol
FDA UNII
IUPAC name
5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride
InChIKey
GHUUBYQTCDQWRA-UHFFFAOYSA-N
- Appearance
- Off-white to pale yellow powder.
- Solubility
- Practically insoluble in water. Soluble in dimethylformamide, slightly soluble in anhydrous ethanol, and very slightly soluble in acetone and acetonitrile.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Strengths are expressed as pioglitazone base: 16.53 mg of the hydrochloride delivers 15 mg.
On the US market
- Reference product
- ActosNDA 021073
- Approved ANDAs
- 11 with a marketed product
- Approved forms and strengths
- Tablet 15 mg, 30 mg, 45 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com